Urteste

Enzyme-based cancer dx · Early cancer detection

Phase 2GPW NewConnectGdańsk

Focus / modality

Enzyme-based cancer dx

Lead asset

Urine cancer test

Type

Diagnostics

Indication

Early cancer detection

Stage

Phase 2

Gdańsk

Capital tier

GPW NewConnect

Backing

GPW NewConnect

Overview

Non-invasive urine tests detecting cancer via tumor-specific enzyme activity; lead program targets pancreatic cancer.

What they do

Urteste S.A. is a Polish diagnostics company developing non-invasive, urine-based cancer tests. Its core technology measures the activity of tumor-specific enzymes excreted in urine, aiming to detect cancers earlier and more simply than imaging or biopsy. Urteste reports a pipeline of around a dozen prototype tests spanning cancers that account for a large share of global cancer deaths.

Lead program & status

Its lead asset is Panuri, an in-vitro diagnostic (IVD) test for pancreatic cancer. Urteste completed Panuri's development cycle in mid-2025, reporting metrics of roughly 89% sensitivity, 75% specificity and 81% overall accuracy. In November 2025 it launched a European multicenter clinical study across centers in Poland, Hungary and Italy, processing urine from about 550 participants, run with CRO partner Aurevia and funded largely by a PARP (Polish Agency for Enterprise Development) grant of around EUR 3m. Interim results are anticipated in 2026 to support CE/IVD certification documentation. In 2024 Urteste also reported a prototype urine test for brain tumors.

Why it matters

Pancreatic cancer is usually detected late and carries poor survival. A cheap, non-invasive urine screen that flags it earlier could meaningfully shift outcomes, and Urteste's enzyme-activity platform is designed to extend across many tumor types.

FAQ

How does Urteste's test work?: It measures the activity of cancer-specific enzymes present in a patient's urine, enabling non-invasive detection.
What is Panuri and what stage is it at?: Panuri is Urteste's lead urine test for pancreatic cancer. After completing development in 2025, it entered a European multicenter clinical study in late 2025, with interim data expected in 2026.
How is the Panuri study funded?: It is funded largely through a grant of around EUR 3 million from Poland's PARP agency.

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.